This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pier, C. L.
Right arrow Articles by Baldwin, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pier, C. L.
Right arrow Articles by Baldwin, M. R.

 Previous Article  |  Next Article 

Infection and Immunity, January 2008, p. 437-442, Vol. 76, No. 1
0019-9567/08/$08.00+0     doi:10.1128/IAI.00843-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Recombinant Holotoxoid Vaccine against Botulism{triangledown}

Christina L. Pier,1 William H. Tepp,1 Marite Bradshaw,1 Eric A. Johnson,1 Joseph T. Barbieri,2 and Michael R. Baldwin2*

Food Research Institute, University of Wisconsin, Madison, Wisconsin,1 Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin2

Received 19 June 2007/ Returned for modification 21 September 2007/ Accepted 10 October 2007

The botulinum neurotoxins (BoNT) are the most toxic proteins for humans and designated "Category A Select Agents." The current vaccine against botulism is in limited supply, and there is a need to develop new vaccine strategies. A recombinant BoNT/A toxoid was produced in Clostridium botulinum that contained a double amino acid substitution, R363A Y365F (termed BoNT/ARYM). BoNT/ARYM was noncatalytic for SNAP25 and nontoxic for mice. Immunization with BoNT/ARYM protected mice from challenge at levels that were similar to chemically inactivated BoNT/A toxoid. BoNT/ARYM elicited an immune response against the light-chain and heavy-chain components of the toxin. Neutralizing anti-BoNT/ARYM sera blocked BoNT toxicity in primary cortical neurons and blocked ganglioside binding by the heavy chain. BoNT/ARYM represents a viable vaccine candidate for a holotoxoid against botulism.

* Corresponding author. Mailing address: Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226. Phone: (414) 456-8419. Fax: (414) 456-6535. E-mail: mbaldwin{at}mcw.edu

{triangledown} Published ahead of print on 29 October 2007.

Editor: V. J. DiRita

Infection and Immunity, January 2008, p. 437-442, Vol. 76, No. 1
0019-9567/08/$08.00+0     doi:10.1128/IAI.00843-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shone, C., Agostini, H., Clancy, J., Gu, M., Yang, H.-H., Chu, Y., Johnson, V., Taal, M., McGlashan, J., Brehm, J., Tong, X. (2009). Bivalent Recombinant Vaccine for Botulinum Neurotoxin Types A and B Based on a Polypeptide Comprising Their Effector and Translocation Domains That Is Protective against the Predominant A and B Subtypes. Infect. Immun. 77: 2795-2801 [Abstract] [Full Text]  
  • Keller, J. E. (2008). Characterization of New Formalin-Detoxified Botulinum Neurotoxin Toxoids. CVI 15: 1374-1379 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»